Looking Into the Future of AML Treatments

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

EP: 13.Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

EP: 14.Key Takeaways From ASH 2024

Now Viewing

EP: 15.Looking Into the Future of AML Treatments

EP: 16.Looking Ahead For the Treatments of R/R MM

EP: 17.Recommendations For Future Clinical Trials in R/R MM

EP: 18.Treatment and Management of MM with Amyloidosis

EP: 19.Highlighting the Key Takeaways From ASH 2024

Video content above is prompted by the following:

The Future of AML Treatments

As advancements in AML treatments evolve, health care professionals must stay informed about emerging therapies and trends. The future of AML management is shaped by novel targeted therapies, immunotherapies, and personalized medicine approaches that improve patient outcomes.

Key areas of development include the following:

• Targeted Therapies: Expanding options like FLT3, IDH1/2, and BCL2 inhibitors tailored to specific genetic mutations
• Immunotherapies: Monoclonal antibodies, chimeric antigen receptor T-cell therapies, and checkpoint inhibitors offer new treatment avenues.
• Personalized Medicine: Advances in genomics and molecular profiling enable more precise treatment strategies.
• Combination Therapies: Optimized regimens integrating new agents with traditional chemotherapy
• Minimal Residual Disease Monitoring: Enhanced detection methods guide treatment decisions and relapse prevention.

Physicians can prepare by staying updated on clinical trials, integrating biomarker testing into routine practice, and adopting multidisciplinary approaches to AML care.